基于数据挖掘的中药复方治疗血脂异常的组方规律及作用机制研究

Study on the medication regularity and mechanism of Chinese herbal compounds in the treatment of dyslipidemia based on data mining

目的基于数据挖掘及网络药理学方法挖掘中药复方治疗血脂异常的组方规律及作用机制,为临床治疗血脂异常提供用药依据。方法检索中国知网、中国生物医学文献数据库、万方数据知识服务平台、维普数据库2010年1月至2020年12月的文献,利用古今医案云平台进行数据分析,获取核心药物,通过中药系统药理学数据库与分析平台,结合文献及Swiss Target Prediction数据库筛选核心药物的活性成分及靶点;通过相关数据库获得疾病靶点,取交集后通过DAVID 6.8进行京都基因和基因组数据库(KEGG)分析,并构建“核心药物-活性成分-靶点-通路”网络。结果共纳入文献969篇,涉及790首方剂、316味中药。结合数据分析结果,获得核心药物:净山楂、丹参、泽泻、茯苓、决明子、白术。核心药物的活性成分靶点有420个,血脂异常疾病靶点1767个,交集靶点132个。“核心药物-活性成分-靶点-通路”网络中的活性成分共有62个,包括槲皮素、24-乙酰泽泻醇A、丹参酮ⅡA、茯苓酸、白术内酯Ⅰ等。KEGG富集通路共有91条,其中与治疗血脂异常相关的通路有HIF-1信号通路、胰岛素信号通路、AMPK信号通路等。结论中医治疗血脂异常多用健脾益气之药补虚,兼用活血化瘀、利湿泻浊、清肝通便之药治标。核心药物对血脂异常的治疗存在分子靶点、化学通路层面的理论及实验依据。临床治疗可参考本研究获取的用药规律及药物作用机制,从而提高临床疗效。

Objective To explore the medication regularity and mechanism of Chinese herbal compounds in the treatment of dyslipidemia based on data mining and network pharmacology methods,so as to provide medication basis for clinical treatment of dyslipidemia.Methods The literatures of CNKI,CBM,Wanfang and VIP databases from January 2010 to December 2020 were retrieved.The ancient and modern consilia cloud platform was used for data analysis to obtain core drugs.The active ingredients and targets of the core drugs were screened by traditional Chinese medicine systems pharmacology database and analysis platform,combined with literatures and Swiss Target Prediction database.Disease targets were obtained through relevant databases,and Kyoto Encyclopedia of Genes and Genomes(KEGG)analysis was performed by DAVID 6.8 after taking the intersection,and a network of core drug-active ingredients-target-pathway was constructed.Results A total of 969 literatures were included,involving 790 prescriptions and 316 Chinese herbs.The data analysis results showed that,the core drugs were included,which were Fructus Crataegi,Radix Salvia Miltiorrhiza,Alismatis Rhizoma,Poria,Cassiae Semen,Atractylodis Macrocephalae Rhizoma.There were 420 active ingredient targets for core drugs,1767 targets for dyslipidemia diseases,and 132 targets for the intersection.The network of core drug-active ingredients-target-pathway had 62 active ingredients,including quercetin,alisol A 24-acetate,tanshinoneⅡA,pachymic acid,atractylenolideⅠ,etc.There were 91 KEGG enrichment pathways,among which,HIF-1 signaling pathway,insulin signaling pathway,AMPK signaling pathway and others were related to the treatment of dyslipidemia.Conclusion In traditional Chinese medicine treatment of dyslipidemia,the herbs of invigorating spleen and benefiting qi are often used for treating deficiency,and the herbs of promoting blood circulation and removing blood stasis,reducing dampness and turbidity,and clearing liver and purging constipation are often used for treating symptoms.There are theoretical and experimental basis for the treatment of core drugs on dyslipidemia at the level of molecular targets and chemical pathways.The drug use rules and drug action mechanism obtained in this study can be referred for clinical treatment,so as to improve the clinical efficacy.